Sandbox:Hannan

Revision as of 18:54, 15 January 2019 by Hannan Javed (talk | contribs)
Jump to navigation Jump to search
Myeloproliferative neoplasms (MPN) Clinical manifestations Diagnosis Other features
Symptoms Physical examination Lab findings Bone marrow biopsy Gold standard Other investigations
WBCs RBCs Platelets
Leukocytosis Blasts Left shift Basophilia Eosinophilia Monocytosis Others
Chronic myeloid leukemia

(CML), BCR-ABL1+

  • Asymptomatic
  • Non-specific
  • Hyperviscosity related
  • Anemia related
  • Bleeding
  • Infection
  • Splenomegaly (46–76%)
  • Purpura
  • Anemia related
  • Priapism
Absolute leukocytosis (median of 100,000/µL) Blasts usually <2% Left shift with classic myelocyte bulge (myelocytes > metamyelocytes on the blood smear)
Absolute basophilia is almost always present Absolute eosinophilia in 90% of patients Often present Anemia Platelet count is usually normal or elevated but thrombocytopenia indicates advanced stage or an alternative diagnosis Bone marrow aspirate and unilateral biopsy with conventional cytogenetics and flow cytometry
Chronic neutrophilic leukemia (CNL)
Polycythemia vera (PV)
Primary myelofibrosis (PMF)
  • prefibrotic/early stage
  • overt fibrotic stage
Essential thrombocythemia (ET)
Chronic eosinophilic leukemia, not otherwise specified (NOS)
MPN, unclassifiable
Mastocytosis
Other myeloid neoplasm and acute leukemia Clinical manifestations Diagnosis Other features
Symptoms Physical examination Lab findings Bone marrow biopsy Gold standard Other investigations
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of

PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2

  • Myeloid/lymphoid neoplasms with PDGFRA rearrangement
  • Myeloid/lymphoid neoplasms with PDGFRB rearrangement
  • Myeloid/lymphoid neoplasms with FGFR1 rearrangement
  • Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
  • Chronic myelomonocytic leukemia (CMML)
  • Atypical chronic myeloid leukemia (aCML), BCR-ABL1-
  • Juvenile myelomonocytic leukemia (JMML)
  • MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
  • MDS/MPN, unclassifiable
Myelodysplastic syndromes (MDS)
  • MDS with single lineage dysplasia
  • MDS with ring sideroblasts (MDS-RS)
  • MDS-RS and single lineage dysplasia
  • MDS-RS and multilineage dysplasia
  • MDS with multilineage dysplasia
  • MDS with excess blasts
  • MDS with isolated del(5q)
  • MDS, unclassifiable
  • Provisional entity: Refractory cytopenia of childhood
  • Myeloid neoplasms with germ line predisposition
Acute myeloid leukemia (AML) and related neoplasms
  • AML with recurrent genetic abnormalities
  1. AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
  2. AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
  3. APL with PML-RARA
  4. AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
  5. AML with t(6;9)(p23;q34.1);DEK-NUP214
  6. AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
  7. AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
  8. Provisional entity: AML with BCR-ABL1
  9. AML with mutated NPM1
  10. AML with biallelic mutations of CEBPA
  11. Provisional entity: AML with mutated RUNX1
  • AML with myelodysplasia-related changes
  • Therapy-related myeloid neoplasms
  • AML, NOS
  1. AML with minimal differentiation
  2. AML without maturation
  3. AML with maturation
  4. Acute myelomonocytic leukemia
  5. Acute monoblastic/monocytic leukemia
  6. Pure erythroid leukemia
  7. Acute megakaryoblastic leukemia
  8. Acute basophilic leukemia
  9. Acute panmyelosis with myelofibrosis
  • Myeloid sarcoma
  • Myeloid proliferations related to Down syndrome
  1. Transient abnormal myelopoiesis (TAM)
  2. Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukemias of ambiguous lineage
  • Acute undifferentiated leukemia
  • Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2);BCR-ABL1
  • MPAL with t(v;11q23.3);KMT2A rearranged
  • MPAL, B/myeloid, NOS
  • MPAL, T/myeloid, NO
B-lymphoblastic leukemia/lymphoma
  • B-lymphoblastic leukemia/lymphoma, NOS
  • B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
  • B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
  • B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
  • B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1
  • B-lymphoblastic leukemia/lymphoma with hyperdiploidy
  • B-lymphoblastic leukemia/lymphoma with hypodiploidy
  • B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
  • B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
  • Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
  • Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP
T-lymphoblastic leukemia/lymphoma
  • Provisional entity: Early T-cell precursor lymphoblastic leukemia
  • Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph
  • 50% of patients are asymptomatic
  • Clinical features are generally nonspecific such as left upper quadrant pain, early satiety, fatigue & lethargy (most common presenting symptom), weight loss, and night sweats.
  • symptoms of anemia
  • bleeding
  • priapism
  • bone pain
  • Abdominal mass or fullness
  • Infection
  • Headache
  • Dyspnoea
  • Visual disturbances
  • Weakness
  • Arthralgia
  • Cough
  • Malaise
  • Dizziness
  • Nausea/vomiting
  • Ankle oedema
  • Mental change